The development of biologic therapeutics using advanced technology to copy and improve on nature's design of complex peptides, proteins, and glycoproteins has enabled the treatment of diseases in entirely new ways and brought unique and lifesaving treatments to many people. However, at least in part because of cost pressures, access to these truly amazing products has not been uniformly available; many patients do not qualify for these treatments, or the treatment is postponed until disabilities accumulate. The development of biosimilars essentially copies of the original biologic drugs after patent expiration allows for wider and, as important, earlier access to these agents because of their lower cost and consequently greater affordability. The development and commercialization of biosimilars can help address unmet medical needs by improving access to well-established therapeutic interventions while improving healthcare affordability.
机构:
Pfizer Global Established Pharma Med, Dev Grp, New York, NY USAPfizer Global Established Pharma Med, Dev Grp, New York, NY USA
AL-Sabbagh, Ahmad
Olech, Ewa
论文数: 0引用数: 0
h-index: 0
机构:
Univ Nevada, Sch Med, Dept Internal Med, 1707 W Charleston Blvd,Suite 220, Las Vegas, NV 89102 USAPfizer Global Established Pharma Med, Dev Grp, New York, NY USA
Olech, Ewa
McClellan, Joseph E.
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Worldwide Res & Dev, BRDU, New York, NY USAPfizer Global Established Pharma Med, Dev Grp, New York, NY USA
McClellan, Joseph E.
Kirchhoff, Carol F.
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Global Supply, Global Technol Serv, BioMfg Sci Grp, Chesterfield, MO USAPfizer Global Established Pharma Med, Dev Grp, New York, NY USA